Catalyst Pharmaceuticals, Inc.
CPRX
Rank in Stocks
#4171
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Share Price
$31.49
Last synced: 2026-07-21
Market Cap
$3.85B
Change (1 day)
0.00%
Change (1 year)
53.24%
Country
US
Trade Catalyst Pharmaceuticals, Inc. (CPRX)
Category
Healthcare
P/B ratio for Catalyst Pharmaceuticals, Inc. (CPRX)
P/B ratio as of October 2026 TTM: 3.80
According to Catalyst Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 3.80. At the end of 2023 the company had a P/B ratio of 4.61.
P/B ratio history for Catalyst Pharmaceuticals, Inc. from 2002 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.80 | 11.81% |
| 2024 | 3.40 | -26.24% |
| 2023 | 4.61 | -28.03% |
| 2022 | 6.40 | 89.14% |
| 2021 | 3.38 | 65.99% |
| 2020 | 2.04 | -53.73% |
| 2019 | 4.41 | 13.53% |
| 2018 | 3.88 | -6.36% |
| 2017 | 4.14 | 87.18% |
| 2016 | 2.21 | -38.01% |
| 2015 | 3.57 | -33.94% |
| 2014 | 5.41 | 30.46% |
| 2013 | 4.14 | 363.73% |
| 2012 | 0.89 | -88.01% |
| 2011 | 7.45 | 123.57% |
| 2010 | 3.33 | 167.55% |
| 2009 | 1.25 | -43.83% |
| 2008 | 2.22 | -16.22% |
| 2007 | 2.65 | 41.50% |
| 2006 | 1.87 | -97.79% |
| 2005 | 84.78 | -44.01% |
| 2004 | 151.41 | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | 320.54 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | 64.44% |
US
|
|
| 13.2547 | 248.67% |
US
|
|
| 4.208 | 10.69% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 62.63% |
NL
|
